Hinge Health’s long-anticipated IPO is generating significant buzz as the first major digital health offering since Waystar’s debut in 2024, raising questions about whether the public markets will value Hinge at or near its prior $6.2 billion private valuation. While the company has shown impressive revenue growth to $390.4M in 2024 and improved margins, concerns remain about future growth beyond the saturated self-insured employer market and its ability to expand beyond musculoskeletal (MSK) care into adjacent areas like behavioral health or GI. As a leader in digital MSK, Hinge faces pressure to either build or buy capabilities in new clinical categories to meet employers’ growing demand for consolidated solutions.
Trending
- The Frontiers of EUS in 2026: A Focus on Novel Needle-Based Devices (GI & Endoscopy News)
- Hybrid Deep Learning Improves Gastrointestinal Image Classification (European Medical Journal)
- Participation in stool-based screening program cut colorectal cancer mortality by 43% (Healio)
- World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System (Business Wire)
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study (PR Newswire)
- Private equity and corporate medicine: what physicians say, in their own words (KevinMD)
- Serrated polyposis often goes unrecognized, task force says (GI & Hepatology News)
- Studies Suggest Longer Colonoscopy Surveillance Intervals May Be Safe (Medscape)
